MCID: LYM026
MIFTS: 55

Lymphoblastic Leukemia malady

Genetic diseases, Immune diseases, Rare diseases, Cancer diseases, Blood diseases categories

Aliases & Classifications for Lymphoblastic Leukemia

About this section

Aliases & Descriptions for Lymphoblastic Leukemia:

Name: Lymphoblastic Leukemia 8 10
Precursor Cell Lymphoblastic Leukemia Lymphoma 61
 
Acute Lymphocytic Leukemia 61
Lymphoid Leukemia 61


Classifications:



External Ids:

Disease Ontology8 DOID:1037
NCIt39 C7539
MeSH33 D007945
ICD9CM27 204.9, 204

Summaries for Lymphoblastic Leukemia

About this section
Disease Ontology:8 A leukemia that has material basis in lymphoblasts (immature white blood cells).

MalaCards based summary: Lymphoblastic Leukemia, also known as precursor cell lymphoblastic leukemia lymphoma, is related to leukemia and precursor b-cell acute lymphoblastic leukemia. An important gene associated with Lymphoblastic Leukemia is TSPAN7 (tetraspanin 7), and among its related pathways are CDO in myogenesis and Lymphocyte Signaling. The drugs mercaptopurine and asparaginase have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related mouse phenotypes are liver/biliary system and tumorigenesis.

Related Diseases for Lymphoblastic Leukemia

About this section

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic 3

Diseases related to Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 351)
idRelated DiseaseScoreTop Affiliating Genes
1leukemia32.2OLIG2, ABCC5, PICALM, MLLT4, BLNK, LMO2
2precursor b-cell acute lymphoblastic leukemia31.7PBX1, FLT3
3lymphoblastic lymphoma31.7FLI1, LMO2
4precursor t-cell acute lymphoblastic leukemia31.3IKZF1, LYL1, FLT3, LMO2, PICALM
5acute leukemia31.3MLLT4, LMO2, FLT3, PBX1, LYL1
6leukemia, acute lymphoblastic31.1ABCC5, PICALM, BLNK, LMO2, FLT3, TCF3
7burkitt lymphoma30.7PICALM, BLNK, LMO2, FLI1, FLT3, PBX1
8breast cancer30.6ABCC5, TPD52L2, LMO2, FLI1, FLT3, PBX1
9acute non lymphoblastic leukemia11.0
10myeloid leukemia10.8
11glucocorticoid resistance10.7
12hematopoietic stem cell transplantation10.7
13childhood leukemia10.7
14hypercalcemia10.6
15sarcoma10.6
16myelodysplastic syndrome10.5
17wilms tumor10.5
18down syndrome10.5
19endotheliitis10.5
20acute lymphoblastic leukemia, childhood10.5
21bone marrow necrosis10.5
22hemophagocytic lymphohistiocytosis10.5
23osteonecrosis10.5
24eosinophilia10.5
25retinitis10.5
26obesity10.5
27hepatitis10.5
28neutropenia10.5
29pancreatitis10.5
30ataxia-telangiectasia10.4
31hypertriglyceridemia10.4
32hodgkin lymphoma10.4
33chronic lymphocytic leukemia10.4
34fusariosis10.4
35cerebritis10.4
36hyperphosphatemia10.4
37acute t cell leukemia10.4
38ataxia10.4
39histiocytic sarcoma10.4
40dysembryoplastic neuroepithelial tumor10.4OLIG2
41bacteremia10.4
42arthritis10.4
43influenza10.4
44meningitis10.4
45neuropathy10.4
46nijmegen breakage syndrome10.3
47b-cell lymphomas10.3
48chronic myelomonocytic leukemia10.3
49myelofibrosis10.3
50severe congenital neutropenia10.3

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia:



Diseases related to lymphoblastic leukemia

Symptoms for Lymphoblastic Leukemia

About this section

Drugs & Therapeutics for Lymphoblastic Leukemia

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Arranon13 38 NELARABINE GlaxoSmithKline Approved October 2005
FDA Label: Arranon
Malady that Drug Treats: Lymphoblastic Leukemia
Indications and Usage:13 ARRANON is a nucleoside metabolic inhibitor indicated for the treatment of; patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic; lymphoma whose disease has not responded to or has relapsed following; treatment with at least two chemotherapy regimens. This use is based on the; induction of complete responses. Randomized trials demonstrating increased; survival or other clinical benefit have not been conducted. (1)
DrugBank Targets:11 DNA
Mechanism of Action:13 
Target: DNA synthesis
Action: disruptor --> apoptosis
FDA: Nelarabine is a pro-drug of the deoxyguanosine analogue 9-²-D-arabinofuranosylguanine; 266 (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase; 267 (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and; 268 subsequently converted to the active 5 -triphosphate, ara-GTP. Accumulation of ara-GTP in; 269 leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition; 270 of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and; 271 systemic toxicity of nelarabine.
2
Marqibo13 38 VINCRISTINE SULFATE Talon Therapeutics Approved August 2012
FDA Label: Marqibo
Malady that Drug Treats: Ph- acute lymphoblastic leukemia
Indications and Usage:13 Marqibo is a vinca alkaloid indicated for the treatment of adult patients with; Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL); in second or greater relapse or whose disease has progressed following two or; more anti-leukemia therapies. This indication is based on overall response; rate. Clinical benefit such as improvement in overall survival has not been; verified (1.1).
DrugBank Targets:11 1. Tubulin beta chain; 2. Tubulin alpha-4A chain
Mechanism of Action:13 
Target: tubulin
Action: alters polymerization equilibrium
FDA: Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate.; Non-liposomal vincristine sulfate binds to tubulin, altering the tubulin polymerization equilibrium, resulting in; altered microtubule structure and function. Non-liposomal vincristine sulfate stabilizes the spindle apparatus,; preventing chromosome segregation, triggering metaphase arrest and inhibition of mitosis.
3
Sprycel13 38 DASATINIB Bristol-Myers Squibb Approved June 2006
FDA Label: Sprycel
Malady that Drug Treats: Chronic Myeloid Leukemia
Indications and Usage:13 SPRYCEL is a kinase inhibitor indicated for the treatment of; newly diagnosed adults with Philadelphia chromosome-positive (Ph+); chronic myeloid leukemia (CML) in chronic phase. (1, 14); adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+; CML with resistance or intolerance to prior therapy including imatinib. (1,; 14); adults with Philadelphia chromosome-positive acute lymphoblastic; leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14)
DrugBank Targets:11 1. Tyrosine-protein kinase ABL1; 2. Proto-oncogene tyrosine-protein kinase Src; 3. Ephrin type-A receptor 2; 4. Tyrosine-protein kinase Lck; 5. Tyrosine-protein kinase Yes; 6. Mast/stem cell growth factor receptor Kit; 7. Platelet-derived growth factor receptor beta; 8. Signal transducer and activator of transcription 5B; 9. Abelson tyrosine-protein kinase 2; 10. Tyrosine-protein kinase Fyn
Mechanism of Action:13 
Target: BCR-ABL, SRC family; (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR² kinases
Action: inhibitor
FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family; (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR². Based on modeling studies, dasatinib is; predicted to bind to multiple conformations of the ABL kinase.; In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate; sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia; (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the; conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABL; kinase domain mutations, activation of alternate signaling pathways involving the SRC; family kinases (LYN, HCK), and multi-drug resistance gene overexpression.

Drug clinical trials:

Search ClinicalTrials for Lymphoblastic Leukemia

Search NIH Clinical Center for Lymphoblastic Leukemia

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Lymphoblastic Leukemia

About this section

Anatomical Context for Lymphoblastic Leukemia

About this section

MalaCards organs/tissues related to Lymphoblastic Leukemia:

31
T cells, B cells, Bone, Bone marrow, Myeloid, B lymphoblasts, Endothelial, Lung, Breast, Brain, Monocytes, Liver, Thymus, Thyroid, Spleen, Whole blood, Kidney, Testes, Neutrophil, Spinal cord, Colon, Skin, Uterus, Placenta, Prostate, Cervix, Tonsil, Temporal lobe, Tongue, Appendix, Pineal, Pituitary

Animal Models for Lymphoblastic Leukemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Lymphoblastic Leukemia:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.6IKZF1, PBX1, FLI1, LMO2, PICALM
2MP:00020069.3TCF3, OLIG2, IKZF1, FLT3, FLI1, LMO2
3MP:00053808.9MLLT4, TCF3, FLI1, PBX1, LMO2, AFF4
4MP:00053878.8ARID5B, IKZF1, LYL1, PBX1, TCF3, FLT3
5MP:00053848.7ARID5B, PBX1, TCF3, FLT3, FLI1, LMO2
6MP:00053978.5TAL2, PICALM, BLNK, AFF4, LMO2, FLI1
7MP:00053788.3TAL2, MLLT4, AFF4, TPD52L2, LMO2, FLI1
8MP:00107688.1PICALM, MLLT4, TAL2, OLIG2, MEF2D, IKZF1

Publications for Lymphoblastic Leukemia

About this section

Articles related to Lymphoblastic Leukemia:

(show top 50)    (show all 2819)
idTitleAuthorsYear
1
Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A. (25903014)
2015
2
Acute lymphoblastic leukemia with eosinophilia lacking peripheral blood leukemic cell: a rare entity. (25332543)
2014
3
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A french multicenter study. (25363877)
2014
4
Renal Infarction Secondary to Invasive Aspergillosis in a 5-Year-Old Girl With Acute Lymphoblastic Leukemia. (24136022)
2013
5
Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia. (24243921)
2013
6
Using a bayesian hierarchical model for identifying single nucleotide polymorphisms associated with childhood acute lymphoblastic leukemia risk in case-parent triads. (24367687)
2013
7
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. (23940221)
2013
8
CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. (24382688)
2013
9
The NR4A orphan nuclear receptors do not confer prednisolone resistance in pediatric acute lymphoblastic leukemia. (24056879)
2013
10
CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. (22261446)
2012
11
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. (22653976)
2012
12
Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. (21261497)
2011
13
Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder. (22184539)
2011
14
Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. (21828118)
2011
15
RUNX1 amplification in B-cell acute lymphoblastic leukemia. (20001241)
2010
16
Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. (19774638)
2010
17
Overt testicular disease at diagnosis in childhood acute lymphoblastic leukemia: prognostic significance and role of testicular irradiation. (20589462)
2010
18
Dense methylation of types 1 and 2 regulatory regions of the CD10 gene promoter in infant acute lymphoblastic leukemia with MLL/AF4 fusion gene. (20051780)
2010
19
Glucocorticoid-regulated microRNAs and mirtrons in acute lymphoblastic leukemia. (19148136)
2009
20
Persistent hypokalemia in an acute lymphoblastic leukemia patient. (20838546)
2009
21
Compromised repair of clustered DNA damage in the human acute lymphoblastic leukemia MSH2-deficient NALM-6 cells. (18955159)
2009
22
Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells. (18599181)
2008
23
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. (18322253)
2008
24
Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia. (18079736)
2008
25
Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region. (17690704)
2007
26
MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. (17512587)
2007
27
Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. (17560996)
2007
28
Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation. (17673463)
2007
29
Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). (16809887)
2006
30
Chemokine IL-8 and chemokine receptor CXCR3 and CXCR4 gene expression in childhood acute lymphoblastic leukemia at first relapse. (16679918)
2006
31
Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells. (16520989)
2006
32
High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia. (16424867)
2006
33
Acquired Glanzmann's thrombasthenia associated with acute lymphoblastic leukemia. (16217260)
2005
34
Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. (15201966)
2004
35
Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression. (12127395)
2002
36
Hematopoietic stem cell transplantation with conditioning regimens containing melphalan in pediatric patients with acute lymphoblastic leukemia]. (12229121)
2002
37
TEL rearrangements in acute lymphoblastic leukemia: association with p16 deletions in relapsed cases. (11410424)
2001
38
The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. (11406533)
2001
39
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia. (11321887)
2001
40
AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. (10756360)
2000
41
High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia. (10397743)
1999
42
The IL-6 gene expression by leukemic cells from acute lymphoblastic leukemia common and T type and modulation of IL-6 production by TNF. (9728802)
1998
43
Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. (9748136)
1998
44
Myeloperoxidase positive acute lymphoblastic leukemia cell lines, NALM-30, NALM-31 and NALM-32, carrying Philadelphia chromosome with biphenotypic characteristics. (10363160)
1998
45
Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. (9058708)
1997
46
Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias. (8634438)
1996
47
Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias. (8637234)
1996
48
Characterization of a 14q+ marker chromosome in philadelphia chromosome positive acute lymphoblastic leukemia by DNA analysis and fluorescence in situ hybridization. (7773965)
1995
49
Shedding of CD9 antigen into cerebrospinal fluid by acute lymphoblastic leukemia cells. (2364164)
1990
50
Acute non-lymphoblastic leukemia. Correlation between clinical and hematological parameters in 87 adult patients. (3121464)
1987

Variations for Lymphoblastic Leukemia

About this section

Expression for genes affiliated with Lymphoblastic Leukemia

About this section
Search GEO for disease gene expression data for Lymphoblastic Leukemia.

Pathways for genes affiliated with Lymphoblastic Leukemia

About this section

Pathways related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.1MEF2D, TCF3
29.6BLNK, FLI1, TCF3, PBX1, IKZF1
39.3LYL1, PBX1, TCF3, TSPAN7, FLT3, FLI1

Compounds for genes affiliated with Lymphoblastic Leukemia

About this section

GO Terms for genes affiliated with Lymphoblastic Leukemia

About this section

Cellular components related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transcription factor complexGO:000566710.0PBX1, TCF3, LMO2
2nucleusGO:00056347.9ARID5B, PICALM, MLLT4, AFF4, LMO2, FLI1

Biological processes related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1Peyers patch developmentGO:004854110.4IKZF1, TCF3
2natural killer cell differentiationGO:000177910.4TCF3, IKZF1
3cell developmentGO:004846810.3ARID5B, TCF3
4thalamus developmentGO:002179410.3OLIG2, TAL2
5embryonic hemopoiesisGO:003516210.2PBX1, LMO2
6adrenal gland developmentGO:003032510.1PBX1, ARID5B
7negative regulation of neuron differentiationGO:004566510.1OLIG2, PBX1
8thymus developmentGO:004853810.1IKZF1, PBX1
9B cell differentiationGO:003018310.0IKZF1, LYL1, TCF3, FLT3, BLNK
10positive regulation of transcription from RNA polymerase II promoterGO:00459449.9BCL9, MEF2D, IKZF1, TCF3, LMO2
11skeletal muscle cell differentiationGO:00359149.8BCL9, MEF2D

Molecular functions related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1bHLH transcription factor bindingGO:004342510.2LMO2, TCF3
2protein dimerization activityGO:004698310.0TAL2, MEF2D, LYL1
3sequence-specific DNA binding RNA polymerase II transcription factor activityGO:000098110.0MEF2D, FLI1, LMO2
4RNA polymerase II regulatory region sequence-specific DNA bindingGO:000097710.0LMO2, MEF2D
5protein heterodimerization activityGO:004698210.0TPD52L2, TCF3, PBX1, IKZF1
6E-box bindingGO:00708889.9TCF3, LMO2
7sequence-specific DNA bindingGO:00435659.8IKZF1, PBX1, TCF3, FLI1
8protein homodimerization activityGO:00428039.8OLIG2, TCF3, FLT3, TPD52L2
9sequence-specific DNA binding transcription factor activityGO:00037009.5AFF4, FLI1, TCF3, PBX1, IKZF1, MEF2D
10DNA bindingGO:00036779.3FLI1, TCF3, PBX1, LYL1, IKZF1, OLIG2
11protein bindingGO:00055158.5ARID5B, PICALM, MLLT4, BLNK, AFF4, TPD52L2

Sources for Lymphoblastic Leukemia

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet